Zearup Biomed

Biotechnology Research • 144 College St, Room 1102, Canada • 1-10 Employees

Company overview

Headquarters	144 College St, Room 1102, Toronto, Ontario M5S 3M2, CA
NAICS	541714
Employees	1-10

Key Contact at Zearup Biomed

Jackie F. Liu

Co-Founder

About Zearup Biomed

🔬 Zearup Biomed | Smart Solutions for Safer Diabetes Care Zearup Biomed is an early-stage biotech startup developing a first-of-its-kind glucose-responsive microneedle patch to proactively prevent hypoglycemia in insulin-dependent patients. Our technology enables automatic glucagon delivery when blood sugar drops—providing a painless, once-daily, and affordable alternative to emergency rescue kits. Rooted in cutting-edge research from the University of Toronto, Zearup aims to bridge innovation and accessibility in diabetes management. Our lead product has shown strong preclinical efficacy in diabetic models, and we’re advancing toward larger animal studies and early-stage commercialization. We are driven by a mission to empower patients and improve quality of life through intelligent, wearable drug delivery systems—starting with hypoglycemia prevention, and expanding to broader protein and peptide therapeutics in the future.

Zearup Biomed revenue & valuation

Annual revenue	$85,555
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$273,776
Total funding	No funding